Cytoplasmic and nuclear programmed death ligand 1 expression in peritumoral stromal cells in breast cancer: Prognostic and predictive value

Table 1 Baseline clinical and pathological information of patients with breast cancer

Breast cancer characteristics	Patients
	n	%
T stage
Т in situ	4	2.7
Т1в	11	7.5
Т1с	89	60.1
Т2	44	29.7
N stage
N0	81	54.7
N1	47	31.8
N2	16	10.8
N3	4	2.7
Histology
Ductal	134	90.5
Lobular	2	1.4
Papillary	4	2.7
Mucinous	4	2.7
Intraductal	4	2.7
Grade (G)
G1	16	10.8
G2	91	61.5
G3	41	27.7
Lymphovascular invasion
Yes	84	56.8
No	64	43.2
Perineural invasion
Yes	115	77.7
No	33	22.3
Molecular biological subtype
Luminal A	56	37.8
Luminal B HER2-negative	66	44.6
Luminal B HER2-positive	10	6.8
Non-luminal HER2-positive	10	6.8
TNBC	6	4.0
ER status
Negative	16	10.8
Positive	132	89.2
PR status
Negative	41	27.7
Positive	107	72.3
HER2 status
Negative	128	85.5
Positive	20	14.5

ER: Estrogen receptor; HER2: Human epidermal growth factor receptor 2; PR: Progesterone receptor; TNBC: Triple-negative breast cancer.